Researchers at Johns Hopkins and the Bloomberg~Kimmel Institute reported that a single blood test using circulating tumor DNA (ctDNA) can indicate—within weeks—whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy. The approach aims to translate tumor-derived genetic material into rapid, clinically actionable readouts. Separately, an overview highlighted blood-based Alzheimer’s assessment as FDA-cleared tests gain traction to identify amyloid pathology earlier with less burden than PET imaging or CSF analysis. Together, these items reflect a broader shift toward liquid biopsy and plasma biomarker strategies as decision-support tools. For biotech and diagnostics stakeholders, the common theme is operational: faster treatment-alignment decisions and wider access due to lower invasiveness—both of which can influence trial design, reimbursement strategy, and clinical uptake.